2024
DOI: 10.1016/j.thromres.2023.12.001
|View full text |Cite
|
Sign up to set email alerts
|

Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism

José Antonio Rueda-Camino,
Raquel Barba,
Sonia Otálora
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 41 publications
0
1
0
Order By: Relevance
“…For example, in the case of the AF population, XANTUS (rivaroxaban), ETNA-AF Europe (edoxaban), and a retrospective study using four large US claims databases: MarketScan, PharMetrics, Optum, and Humana (apixaban), showed a similar clinical profile compared to our study, but in contrast to our data, these studies had a very limited follow-up [ 34 , 35 , 36 ]. On the other hand, in the RIETE registry, which included patients with VTE in Spain, those patients taking DOACs were older and had more comorbidities than those reported in the phase 3 clinical trials [ 37 ]. Therefore, our data are very relevant, since they may provide current information about patients taking FXai in Spain and the real incidence of bleeding in clinical practice.…”
Section: Discussionmentioning
confidence: 99%
“…For example, in the case of the AF population, XANTUS (rivaroxaban), ETNA-AF Europe (edoxaban), and a retrospective study using four large US claims databases: MarketScan, PharMetrics, Optum, and Humana (apixaban), showed a similar clinical profile compared to our study, but in contrast to our data, these studies had a very limited follow-up [ 34 , 35 , 36 ]. On the other hand, in the RIETE registry, which included patients with VTE in Spain, those patients taking DOACs were older and had more comorbidities than those reported in the phase 3 clinical trials [ 37 ]. Therefore, our data are very relevant, since they may provide current information about patients taking FXai in Spain and the real incidence of bleeding in clinical practice.…”
Section: Discussionmentioning
confidence: 99%